Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 401 - 500
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 401 | 26888584 |
US |
2 | |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 402 | 26888592 |
US |
1 | 2 |
Dermatitis, Dermatitis atopic, Product use in unapproved indication, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 403 | 26888948 |
US |
28 | 2 |
Dermatitis atopic, Skin exfoliation, Skin haemorrhage, Product dose omission issue, Therapeutic response shortened, |
||||
DUPILUMAB, NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, TRETINOIN, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 404 | 26888976 |
US |
14 | 1 |
Dry skin, Eye allergy, Ocular hyperaemia, Dry eye, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 405 | 26888979 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 406 | 26889381 |
US |
75 | 2 |
Diverticulitis, Fungal skin infection, Sciatica, Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, TERIPARATIDE, |
||||
| 407 | 26889485 |
US |
||
Dermatitis atopic, Cough, Pruritus, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 408 | 26889686 |
US |
39 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 409 | 26889705 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE GEL USP, 1%, CLINDAMYCIN PHOSPHATE TOPICAL, LISINOPRIL, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, TAMSULOSIN HYDROCHLORIDE, |
||||
| 410 | 26889716 |
US |
53 | 2 |
Dermatitis atopic, Erythema, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 411 | 26889729 |
US |
82 | 1 |
Dermatitis allergic, Dermatitis atopic, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 412 | 26889780 |
US |
11 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 413 | 26890065 |
US |
15 | 2 |
Pruritus, Therapeutic response shortened, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 414 | 26890122 |
US |
65 | 1 |
Dermatitis atopic, Rash, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 415 | 26890322 |
US |
12 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 416 | 26890361 |
GB |
||
Dry skin, Rash, Dermatitis atopic, Skin exfoliation, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 417 | 26890590 |
US |
36 | 2 |
Dermatitis atopic, Pruritus, Dry skin, |
||||
DUPILUMAB, |
||||
| 418 | 26890604 |
US |
23 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 419 | 26891325 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 420 | 26891623 |
US |
1 | |
Injection site pain, Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, MELATONIN, |
||||
| 421 | 26891629 |
US |
2 | |
Mast cell activation syndrome, Injection site pain, Injection site erythema, Dermatitis atopic, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE, CETIRIZINE HCL, CETIRIZINE, CHLORDIAZEPOXIDE HYDROCHLORIDE, DOCUSATE SODIUM, DOCUSATE SODIUM - SENNOSIDES, DICYCLOMINE HYDROCHLORIDE, GALCANEZUMAB-GNLM, EPINEPHRINE, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, FAMOTIDINE, HYDROXYCHLOROQUINE SULFATE, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, TENAPANOR HYDROCHLORIDE, GLUTATHIONE, KOJIC ACIDSKIN LIGHTENING, LAMOTRIGINE, MAGNESIUM, METRONIDAZOLE, METRONIDAZOLE TOPICAL, NALTREXONE, RIMEGEPANT SULFATE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, PIMECROLIMUS, PRAZOSIN HYDROCHLORIDE, QUETIAPINE, MONTELUKAST SODIUM, SULINDAC, ERGOCALCIFEROL, |
||||
| 422 | 26891762 |
US |
1 | |
Dermatitis atopic, Therapeutic product effect incomplete, |
||||
DUPILUMAB, |
||||
| 423 | 26881260 |
US |
40 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 424 | 26881410 |
US |
63 | 1 |
Skin swelling, Skin ulcer, Dermatitis atopic, Eczema, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 425 | 26881419 |
US |
2 | |
Eczema, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, FEXOFENADINE HYDROCHLORIDE, IRON, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, PIMECROLIMUS, ERGOCALCIFEROL, TAPINAROF, |
||||
| 426 | 26881423 |
US |
95 | 2 |
Dermatitis atopic, Burning sensation, |
||||
DUPILUMAB, |
||||
| 427 | 26881649 |
US |
2 | |
Discomfort, Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 428 | 26881662 |
US |
66 | 2 |
Malaise, Nausea, Fatigue, Thinking abnormal, Injection site bruising, Dermatitis atopic, |
||||
DUPILUMAB, LEVETIRACETAM, LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LISINOPRIL, LORAZEPAM, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, PANTOPRAZOLE, EVOLOCUMAB, RESMETIROM, |
||||
| 429 | 26881893 |
US |
56 | 2 |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 430 | 26881896 |
US |
69 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 431 | 26881911 |
US |
10 | 2 |
Dermatitis atopic, Dry skin, Erythema, |
||||
DUPILUMAB, |
||||
| 432 | 26881913 |
US |
75 | 1 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 433 | 26881917 |
US |
2 | |
Pulmonary oedema, Skin exfoliation, Skin swelling, Lymphadenopathy, Dermatitis atopic, Rash, Hypersensitivity, |
||||
DUPILUMAB, CETIRIZINE HCL, CETIRIZINE, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, CLONAZEPAM, AMPHETAMINE, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, GABAPENTIN, METRONIDAZOLE, METRONIDAZOLE TOPICAL, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, TIZANIDINE HYDROCHLORIDE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, VORTIOXETINE, PYRITHIONE ZINC, ERGOCALCIFEROL, LIFITEGRAST, |
||||
| 434 | 26881921 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 435 | 26882170 |
US |
2 | |
Injection site reaction, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 436 | 26882174 |
US |
14 | 1 |
Dermatitis atopic, Pruritus, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 437 | 26882210 |
US |
19 | 2 |
Dermatitis atopic, Dry skin, |
||||
DUPILUMAB, |
||||
| 438 | 26882218 |
US |
33 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 439 | 26882469 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 440 | 26882478 |
US |
2 | |
Blister, Dermatitis atopic, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 441 | 26882574 |
US |
48 | |
Dermatitis atopic, Eczema, Product dose omission issue, Off label use, Intentional underdose, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 442 | 26882800 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 443 | 26883110 |
US |
53 | |
Dermatitis atopic, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 444 | 26883184 |
US |
13 | 2 |
Dermatitis atopic, Rash, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 445 | 26883227 |
US |
89 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, NAPROXEN SODIUM, NAPROXEN SODIUM TABLET, TRIAMTERENE CAPSULES, TRIAMTERENE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, CITALOPRAM, CITALOPRAM HYDROBROMIDE, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, BETAMETHASONE DIPROPIONATE, MUPIROCIN, MUPIROCIN CALCIUM, PREDNISONE, |
||||
| 446 | 26883714 |
US |
84 | 2 |
Brain fog, Headache, Pain, Insomnia, Depression, Myalgia, Anxiety, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 447 | 26883721 |
US |
15 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 448 | 26883757 |
US |
56 | 2 |
Back pain, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 449 | 26884170 |
US |
||
Cutaneous T-cell lymphoma, Condition aggravated, Eczema, Dermatitis atopic, Pyrexia, Chills, Pain, Injury, Emotional distress, Anhedonia, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 450 | 26884179 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 451 | 26884200 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 452 | 26884220 |
US |
50 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 453 | 26884671 |
US |
18 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 454 | 26884708 |
US |
8 | 1 |
Arthropod bite, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 455 | 26884711 |
US |
2 | |
Dermatitis atopic, Neurodermatitis, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 456 | 26884973 |
US |
41 | 2 |
Eye irritation, Dermatitis atopic, Dry eye, |
||||
DUPILUMAB, |
||||
| 457 | 26884977 |
US |
1 | |
Dermatitis atopic, Rash, Discomfort, |
||||
DUPILUMAB, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCLYCLINE HYCLATE, |
||||
| 458 | 26885437 |
US |
71 | 2 |
Cancer surgery, Sinus operation, Sinusitis, Oropharyngeal pain, Ear pain, Vertigo, Dizziness, Dermatitis atopic, |
||||
UPADACITINIB, |
||||
| 459 | 26885747 |
US |
6 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 460 | 26885749 |
US |
1 | |
Dry skin, Skin fissures, Skin weeping, Skin haemorrhage, Pruritus, Eczema, Dry eye, Eye pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 461 | 26885845 |
US |
77 | 2 |
Limb operation, Neuropathy peripheral, Arthritis, Dermatitis atopic, Nervous system disorder, Rash, Post procedural complication, |
||||
UPADACITINIB, UPADACITINIB, |
||||
| 462 | 26886113 |
US |
2 | 2 |
Dermatitis atopic, Pruritus, Erythema, Therapeutic response decreased, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 463 | 26886417 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 464 | 26886495 |
US |
55 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 465 | 26886497 |
US |
27 | 1 |
Dermatitis atopic, Erythema, Rash, |
||||
DUPILUMAB, |
||||
| 466 | 26876035 |
US |
22 | 1 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 467 | 26876049 |
US |
17 | 2 |
Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, |
||||
| 468 | 26876261 |
US |
26 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 469 | 26876304 |
US |
68 | 1 |
Dermatitis atopic, Cough, Rhinorrhoea, Product dose omission issue, |
||||
BUDESONIDE, |
||||
| 470 | 26876646 |
US |
50 | 2 |
Dermatitis atopic, Rash, Skin discomfort, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 471 | 26876670 |
US |
4 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 472 | 26876678 |
US |
71 | 2 |
Dermatitis atopic, Skin irritation, Erythema, Rash, |
||||
DUPILUMAB, |
||||
| 473 | 26877146 |
US |
3 | 1 |
Dermatitis atopic, Dermatitis allergic, Condition aggravated, Rash macular, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 474 | 26877149 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 475 | 26877177 |
US |
24 | 1 |
Dermatitis atopic, Allergy to animal, |
||||
DUPILUMAB, |
||||
| 476 | 26877841 |
US |
2 | |
Dermatitis atopic, Hand dermatitis, |
||||
DUPILUMAB, |
||||
| 477 | 26877847 |
US |
31 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 478 | 26878168 |
US |
2 | |
Drug ineffective, Dyspnoea, Dry skin, Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, BIOTIN, GABAPENTIN, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, PANTOPRAZOLE SODIUM, FEXOFENADINE HYDROCHLORIDE, BIOTIN, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, NEMOLIZUMAB-ILTO, MAGNESIUM, |
||||
| 479 | 26878174 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 480 | 26878186 |
US |
47 | 2 |
Dermatitis atopic, Pruritus, Skin haemorrhage, Rash, Infection, Skin fissures, Discomfort, Sleep disorder due to a general medical condition, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 481 | 26878205 |
US |
31 | 2 |
Dermatitis atopic, Injection site reaction, Drug hypersensitivity, |
||||
DUPILUMAB, |
||||
| 482 | 26878554 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 483 | 26879718 |
CN |
59 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 484 | 26880204 |
US |
2 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, CETIRIZINE HYDROCHLORIDE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 485 | 26880221 |
US |
79 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 486 | 26880395 |
US |
73 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, CABOTEGRAVIR AND RILPIVIRINE, |
||||
| 487 | 26881036 |
US |
2 | |
Dermatitis allergic, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, |
||||
| 488 | 26881199 |
US |
46 | |
Dermatitis atopic, Sleep disorder, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 489 | 26875161 |
US |
5 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 490 | 26875162 |
US |
65 | 2 |
Stress, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 491 | 26875185 |
US |
28 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 492 | 26875187 |
US |
76 | 1 |
Dermatitis atopic, Peripheral swelling, Incorrect route of product administration, |
||||
DUPILUMAB, |
||||
| 493 | 26875248 |
US |
68 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, LEBRIKIZUMAB-LBKZ, |
||||
| 494 | 26875269 |
US |
87 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 495 | 26875332 |
US |
40 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 496 | 26875412 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 497 | 26875427 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 498 | 26875435 |
US |
30 | 2 |
Sleep disorder due to a general medical condition, Dermatitis atopic, Rash, Drug ineffective, |
||||
DUPILUMAB, DEXTROAMPHETAMINE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, PREDNISONE, |
||||
| 499 | 26875512 |
US |
38 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 500 | 26875513 |
US |
3 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30